RT Journal Article
SR Electronic
T1 Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.10.16.464660
DO 10.1101/2021.10.16.464660
A1 Kah-Whye Peng
A1 Timothy Carey
A1 Patrycja Lech
A1 Rianna Vandergaast
A1 Miguel Á. Muñoz-Alía
A1 Nandakumar Packiriswamy
A1 Clement Gnanadurai
A1 Karina Krotova
A1 Mulu Tesfay
A1 Christopher Ziegler
A1 Michelle Haselton
A1 Kara Sevola
A1 Chase Lathrum
A1 Samantha Reiter
A1 Riya Narjari
A1 Baskar Balakrishnan
A1 Lukkana Suksanpaisan
A1 Toshie Sakuma
A1 Jordan Recker
A1 Lianwen Zhang
A1 Scott Waniger
A1 Luke Russell
A1 Christopher D. Petro
A1 Christos A. Kyratsous
A1 Alina Baum
A1 Jody L. Janecek
A1 Rachael M. Lee
A1 Sabarinathan Ramachandran
A1 Melanie L. Graham
A1 Stephen J. Russell
YR 2021
UL http://biorxiv.org/content/early/2021/10/18/2021.10.16.464660.abstract
AB An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.Competing Interest StatementImanis and Vyriad authors own options/shares in the companies. This work has been described in one or more pending provisional patent applications. KWP and SJR are officers of Imanis and Vyriad.